Financhill
Sell
36

NSPR Quote, Financials, Valuation and Earnings

Last price:
$2.72
Seasonality move :
-23.38%
Day range:
$2.66 - $2.80
52-week range:
$1.81 - $3.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.19x
P/B ratio:
1.72x
Volume:
42.4K
Avg. volume:
29.5K
1-year change:
-13.24%
Market cap:
$71.1M
Revenue:
$6.2M
EPS (TTM):
-$0.72

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NSPR
InspireMD
$1.8M -$0.20 4.09% -53.85% $4.50
ABT
Abbott Laboratories
$11B $1.34 6.82% 59.57% $130.62
CATX
Perspective Therapeutics
$286.4K -$0.26 -- -70.12% $16.15
RVP
Retractable Technologies
-- -- -- -- --
VTAK
Catheter Precision
$280K -$0.20 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$31.8M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NSPR
InspireMD
$2.72 $4.50 $71.1M -- $0.00 0% 15.19x
ABT
Abbott Laboratories
$113.48 $130.62 $196.8B 34.49x $0.59 1.97% 4.81x
CATX
Perspective Therapeutics
$3.43 $16.15 $231.8M -- $0.00 0% 18.52x
RVP
Retractable Technologies
$0.79 -- $23.6M -- $0.00 0% 0.62x
VTAK
Catheter Precision
$0.46 -- $3.7M 0.52x $0.00 0% 1.22x
XTNT
Xtant Medical Holdings
$0.52 -- $72.3M -- $0.00 0% 0.61x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NSPR
InspireMD
-- 3.047 -- 5.87x
ABT
Abbott Laboratories
27.35% 0.781 8.05% 1.14x
CATX
Perspective Therapeutics
-- -3.977 -- --
RVP
Retractable Technologies
1.55% -0.169 11.72% 5.80x
VTAK
Catheter Precision
12% -4.376 128.21% 0.53x
XTNT
Xtant Medical Holdings
43.2% 0.300 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NSPR
InspireMD
$414K -$8.5M -68.55% -68.55% -467.51% -$6.1M
ABT
Abbott Laboratories
$5.9B $1.9B 10.69% 14.78% 19.58% $2.1B
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
RVP
Retractable Technologies
-$14.8K -$5.1M -16.57% -16.83% -18.58% -$6.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

InspireMD vs. Competitors

  • Which has Higher Returns NSPR or ABT?

    Abbott Laboratories has a net margin of -435.91% compared to InspireMD's net margin of 15.48%. InspireMD's return on equity of -68.55% beat Abbott Laboratories's return on equity of 14.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    NSPR
    InspireMD
    22.87% -$0.16 $41.4M
    ABT
    Abbott Laboratories
    55.83% $0.94 $55B
  • What do Analysts Say About NSPR or ABT?

    InspireMD has a consensus price target of $4.50, signalling upside risk potential of 74.36%. On the other hand Abbott Laboratories has an analysts' consensus of $130.62 which suggests that it could grow by 15.11%. Given that InspireMD has higher upside potential than Abbott Laboratories, analysts believe InspireMD is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    NSPR
    InspireMD
    0 0 0
    ABT
    Abbott Laboratories
    13 6 0
  • Is NSPR or ABT More Risky?

    InspireMD has a beta of 0.995, which suggesting that the stock is 0.496% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.734, suggesting its less volatile than the S&P 500 by 26.571%.

  • Which is a Better Dividend Stock NSPR or ABT?

    InspireMD has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.97% to investors and pays a quarterly dividend of $0.59 per share. InspireMD pays -- of its earnings as a dividend. Abbott Laboratories pays out 62.14% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NSPR or ABT?

    InspireMD quarterly revenues are $1.8M, which are smaller than Abbott Laboratories quarterly revenues of $10.6B. InspireMD's net income of -$7.9M is lower than Abbott Laboratories's net income of $1.6B. Notably, InspireMD's price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 34.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD is 15.19x versus 4.81x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NSPR
    InspireMD
    15.19x -- $1.8M -$7.9M
    ABT
    Abbott Laboratories
    4.81x 34.49x $10.6B $1.6B
  • Which has Higher Returns NSPR or CATX?

    Perspective Therapeutics has a net margin of -435.91% compared to InspireMD's net margin of --. InspireMD's return on equity of -68.55% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NSPR
    InspireMD
    22.87% -$0.16 $41.4M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About NSPR or CATX?

    InspireMD has a consensus price target of $4.50, signalling upside risk potential of 74.36%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 370.85%. Given that Perspective Therapeutics has higher upside potential than InspireMD, analysts believe Perspective Therapeutics is more attractive than InspireMD.

    Company Buy Ratings Hold Ratings Sell Ratings
    NSPR
    InspireMD
    0 0 0
    CATX
    Perspective Therapeutics
    7 1 0
  • Is NSPR or CATX More Risky?

    InspireMD has a beta of 0.995, which suggesting that the stock is 0.496% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

  • Which is a Better Dividend Stock NSPR or CATX?

    InspireMD has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NSPR or CATX?

    InspireMD quarterly revenues are $1.8M, which are larger than Perspective Therapeutics quarterly revenues of --. InspireMD's net income of -$7.9M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, InspireMD's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD is 15.19x versus 18.52x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NSPR
    InspireMD
    15.19x -- $1.8M -$7.9M
    CATX
    Perspective Therapeutics
    18.52x -- -- -$15.1M
  • Which has Higher Returns NSPR or RVP?

    Retractable Technologies has a net margin of -435.91% compared to InspireMD's net margin of -18.58%. InspireMD's return on equity of -68.55% beat Retractable Technologies's return on equity of -16.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    NSPR
    InspireMD
    22.87% -$0.16 $41.4M
    RVP
    Retractable Technologies
    -0.14% -$0.07 $84.8M
  • What do Analysts Say About NSPR or RVP?

    InspireMD has a consensus price target of $4.50, signalling upside risk potential of 74.36%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that InspireMD has higher upside potential than Retractable Technologies, analysts believe InspireMD is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    NSPR
    InspireMD
    0 0 0
    RVP
    Retractable Technologies
    0 0 0
  • Is NSPR or RVP More Risky?

    InspireMD has a beta of 0.995, which suggesting that the stock is 0.496% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.939, suggesting its more volatile than the S&P 500 by 93.884%.

  • Which is a Better Dividend Stock NSPR or RVP?

    InspireMD has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

  • Which has Better Financial Ratios NSPR or RVP?

    InspireMD quarterly revenues are $1.8M, which are smaller than Retractable Technologies quarterly revenues of $10.3M. InspireMD's net income of -$7.9M is lower than Retractable Technologies's net income of -$1.9M. Notably, InspireMD's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD is 15.19x versus 0.62x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NSPR
    InspireMD
    15.19x -- $1.8M -$7.9M
    RVP
    Retractable Technologies
    0.62x -- $10.3M -$1.9M
  • Which has Higher Returns NSPR or VTAK?

    Catheter Precision has a net margin of -435.91% compared to InspireMD's net margin of -4291.67%. InspireMD's return on equity of -68.55% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    NSPR
    InspireMD
    22.87% -$0.16 $41.4M
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About NSPR or VTAK?

    InspireMD has a consensus price target of $4.50, signalling upside risk potential of 74.36%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 335.73%. Given that Catheter Precision has higher upside potential than InspireMD, analysts believe Catheter Precision is more attractive than InspireMD.

    Company Buy Ratings Hold Ratings Sell Ratings
    NSPR
    InspireMD
    0 0 0
    VTAK
    Catheter Precision
    0 0 0
  • Is NSPR or VTAK More Risky?

    InspireMD has a beta of 0.995, which suggesting that the stock is 0.496% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.184, suggesting its less volatile than the S&P 500 by 118.441%.

  • Which is a Better Dividend Stock NSPR or VTAK?

    InspireMD has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NSPR or VTAK?

    InspireMD quarterly revenues are $1.8M, which are larger than Catheter Precision quarterly revenues of $96K. InspireMD's net income of -$7.9M is lower than Catheter Precision's net income of -$4.1M. Notably, InspireMD's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD is 15.19x versus 1.22x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NSPR
    InspireMD
    15.19x -- $1.8M -$7.9M
    VTAK
    Catheter Precision
    1.22x 0.52x $96K -$4.1M
  • Which has Higher Returns NSPR or XTNT?

    Xtant Medical Holdings has a net margin of -435.91% compared to InspireMD's net margin of -17.98%. InspireMD's return on equity of -68.55% beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    NSPR
    InspireMD
    22.87% -$0.16 $41.4M
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About NSPR or XTNT?

    InspireMD has a consensus price target of $4.50, signalling upside risk potential of 74.36%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 332.69%. Given that Xtant Medical Holdings has higher upside potential than InspireMD, analysts believe Xtant Medical Holdings is more attractive than InspireMD.

    Company Buy Ratings Hold Ratings Sell Ratings
    NSPR
    InspireMD
    0 0 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is NSPR or XTNT More Risky?

    InspireMD has a beta of 0.995, which suggesting that the stock is 0.496% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

  • Which is a Better Dividend Stock NSPR or XTNT?

    InspireMD has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NSPR or XTNT?

    InspireMD quarterly revenues are $1.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. InspireMD's net income of -$7.9M is lower than Xtant Medical Holdings's net income of -$5M. Notably, InspireMD's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD is 15.19x versus 0.61x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NSPR
    InspireMD
    15.19x -- $1.8M -$7.9M
    XTNT
    Xtant Medical Holdings
    0.61x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Trump Presidency Means For Stock Market
What Trump Presidency Means For Stock Market

Donald Trump was the first president in modern U.S. history…

Where Will TJX Companies Stock Be in 10 Years?
Where Will TJX Companies Stock Be in 10 Years?

Off-price retail is as popular as ever thanks to social…

Will CVS Health Stock Recover?
Will CVS Health Stock Recover?

It’s been a treacherous journey for CVS Health Corporation (NYSE:CVS)…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
45
QMCO alert for Jan 16

Quantum [QMCO] is down 0% over the past day.

Buy
51
QRVO alert for Jan 16

Qorvo [QRVO] is down 0% over the past day.

Sell
31
ATEX alert for Jan 16

Anterix [ATEX] is down 0% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock